Every investor in Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd. (SHSE:900904) should be aware of the most powerful shareholder groups. We can see that individual investors own the lion's share in the company with 46% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
Clearly, individual investors benefitted the most after the company's market cap rose by US$74m last week.
Let's take a closer look to see what the different types of shareholders can tell us about Shanghai Shenqi Pharmaceutical Investment Management.
View our latest analysis for Shanghai Shenqi Pharmaceutical Investment Management
![ownership-breakdown](https://usnewsfile.futunn.com/pic/0-17253971-0-bcdf26c7fc3d1fe22cd2118ce7c0bed7.png/big)
SHSE:900904 Ownership Breakdown November 30th 2022
What Does The Institutional Ownership Tell Us About Shanghai Shenqi Pharmaceutical Investment Management?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
Since institutions own only a small portion of Shanghai Shenqi Pharmaceutical Investment Management, many may not have spent much time considering the stock. But it's clear that some have; and they liked it enough to buy in. So if the company itself can improve over time, we may well see more institutional buyers in the future. We sometimes see a rising share price when a few big institutions want to buy a certain stock at the same time. The history of earnings and revenue, which you can see below, could be helpful in considering if more institutional investors will want the stock. Of course, there are plenty of other factors to consider, too.
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17253971-1-324398a22f65e6ccb8cf95ae58f5d4e9.png/big)
SHSE:900904 Earnings and Revenue Growth November 30th 2022
We note that hedge funds don't have a meaningful investment in Shanghai Shenqi Pharmaceutical Investment Management. The company's largest shareholder is Guizhou Shenqi Group Holding Co., Ltd., with ownership of 23%. With 16% and 12% of the shares outstanding respectively, Guizhou Maijisi Investment Management Co., Ltd. and Zhiting Zhang are the second and third largest shareholders. Zhiting Zhang, who is the third-largest shareholder, also happens to hold the title of Chairman of the Board.
A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 51% stake.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Shanghai Shenqi Pharmaceutical Investment Management
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
Our most recent data indicates that insiders own a reasonable proportion of Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd.. Insiders have a US$99m stake in this US$739m business. This may suggest that the founders still own a lot of shares. You can click here to see if they have been buying or selling.
General Public Ownership
The general public, who are usually individual investors, hold a 46% stake in Shanghai Shenqi Pharmaceutical Investment Management. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Company Ownership
It seems that Private Companies own 39%, of the Shanghai Shenqi Pharmaceutical Investment Management stock. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for Shanghai Shenqi Pharmaceutical Investment Management (2 can't be ignored) that you should be aware of.
Of course this may not be the best stock to buy. So take a peek at this free free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
上海申奇医药投资管理有限公司(上证号:900904)的每一位投资者都应该意识到最强大的股东群体。我们可以看到,个人投资者拥有46%的股份,拥有公司的最大份额。换句话说,该集团将从他们对公司的投资中获得最大(或损失最大)。
显然,在该公司市值上周上涨7400万美元后,散户投资者受益最大。
让我们仔细看看不同类型的股东对上海申奇医药投资管理公司有什么启示。
查看我们对上海申祺医药投资管理的最新分析
![ownership-breakdown](https://usnewsfile.futunn.com/pic/0-17253971-0-bcdf26c7fc3d1fe22cd2118ce7c0bed7.png/big)
上海证交所:900904所有权明细2022年11月30日
机构持股对上海申奇医药投资管理公司有何启示?
机构投资者通常将自己的回报与经常跟踪的指数的回报进行比较。因此,他们通常确实会考虑收购被纳入相关基准指数的较大公司。
由于机构只持有上海申奇医药投资管理公司的一小部分股份,许多机构可能没有花太多时间考虑这只股票。但很明显,有些人已经这样做了;他们非常喜欢它,于是就买入了。因此,如果公司本身能够随着时间的推移而改善,我们很可能会在未来看到更多的机构买家。当几家大机构想要同时购买某只股票时,我们有时会看到股价上涨。下面你可以看到的收益和收入的历史,可能有助于考虑是否有更多的机构投资者会想要这只股票。当然,还有很多其他因素需要考虑。
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-17253971-1-324398a22f65e6ccb8cf95ae58f5d4e9.png/big)
上海证交所:900904收益和收入增长2022年11月30日
我们注意到,对冲基金在上海申奇医药投资管理公司没有有意义的投资。该公司第一大股东为贵州神启集团控股有限公司,持股23%。贵州麦积思投资管理有限公司和张智亭分别持有16%和12%的流通股,是第二大股东和第三大股东。第三大股东张智亭也恰好持有董事长头衔。
对股东登记的更详细的研究表明,三大股东通过他们51%的股份在公司中拥有相当大的所有权。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。我们的信息显示,分析师没有对该股进行任何报道,因此它可能鲜为人知。
上海申奇医药投资管理公司的内部人持股
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。管理层最终要向董事会负责。然而,经理人担任执行董事会成员并不少见,尤其是如果他们是创始人或首席执行官的话。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
我们的最新数据显示,内部人士持有上海申奇医药投资管理有限公司的合理比例。在这项价值7.39亿美元的业务中,内部人士持有9900万美元的股份。这可能表明,创始人仍持有大量股份。您可以单击此处查看他们是在买入还是在卖出。
一般公有制
一般公众通常是个人投资者,他们持有上海申奇医药投资管理公司46%的股份。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私营公司所有权
看来,民营企业持有上海申奇医药投资管理公司39%的股份。或许有必要对此进行更深入的研究。如果关联方,如内部人士,对这些私营公司中的一家有利害关系,则应在年报中披露。私营公司也可能对该公司拥有战略利益。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。例如,我们已经确定上海申奇医药投资管理的3个警示(2)你应该知道的。
当然了这可能不是最值得购买的股票。。所以让我们来看看这个免费 免费有趣的公司名单。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。